A detailed history of Raleigh Capital Management Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Raleigh Capital Management Inc. holds 33,197 shares of GILD stock, worth $3.12 Million. This represents 1.09% of its overall portfolio holdings.

Number of Shares
33,197
Previous 25,396 30.72%
Holding current value
$3.12 Million
Previous $1.74 Million 59.7%
% of portfolio
1.09%
Previous 0.75%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$66.59 - $83.99 $519,468 - $655,205
7,801 Added 30.72%
33,197 $2.78 Million
Q2 2024

Jul 31, 2024

BUY
$63.15 - $72.88 $78,811 - $90,954
1,248 Added 5.17%
25,396 $1.74 Million
Q1 2024

May 13, 2024

BUY
$71.58 - $87.29 $327,550 - $399,439
4,576 Added 23.38%
24,148 $1.77 Million
Q4 2023

Feb 21, 2024

SELL
$73.27 - $83.09 $29,014 - $32,903
-396 Reduced 1.98%
19,572 $1.59 Million
Q3 2023

Dec 07, 2023

BUY
$73.94 - $80.67 $12,569 - $13,713
170 Added 0.86%
19,968 $1.5 Million
Q3 2023

Dec 06, 2023

BUY
$73.94 - $80.67 $146,253 - $159,565
1,978 Added 11.1%
19,798 $1.48 Million
Q2 2023

Jul 25, 2023

SELL
$76.01 - $86.7 $724,223 - $826,077
-9,528 Reduced 34.84%
17,820 $1.37 Million
Q1 2023

May 22, 2023

SELL
$77.31 - $88.08 $1.48 Million - $1.69 Million
-19,149 Reduced 41.18%
27,348 $2.27 Million
Q4 2022

Feb 07, 2023

SELL
$62.32 - $89.47 $244,543 - $351,080
-3,924 Reduced 7.78%
46,497 $3.99 Million
Q3 2022

Nov 09, 2022

BUY
$59.54 - $68.01 $603,735 - $689,621
10,140 Added 25.17%
50,421 $3.11 Million
Q2 2022

Aug 30, 2022

BUY
$57.72 - $65.01 $751,110 - $845,975
13,013 Added 47.72%
40,281 $2.49 Million
Q1 2022

May 12, 2022

BUY
$57.92 - $72.58 $1.58 Million - $1.97 Million
27,194 Added 36748.65%
27,268 $1.62 Million
Q4 2021

Feb 16, 2022

BUY
$64.88 - $73.64 $4,801 - $5,449
74 New
74 $5,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Raleigh Capital Management Inc. Portfolio

Follow Raleigh Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raleigh Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raleigh Capital Management Inc. with notifications on news.